Merck & Co. has penned a $300 million biobucks-per-product deal with cancer biotech Epitopea to identify previously secret ...

Merck (NYSE: MRK) recently released its Q4 results, with revenues and earnings exceeding the street estimates.

The 12-month price targets assessed by analysts reveal further insights, featuring an average target of $112.46, a high ...

Earnings Call Insights: Merck & Co., Inc. (NYSE ... an increase due to reduced royalty rates and favorable product mix. Operating expenses decreased, reflecting lower licensing-related charges ...

Biopharmaceutical company Merck & Co., Inc. (MRK) reported Tuesday a net profit for the fourth quarter compared to a loss last year, ...

Merck & Co., Inc. operates as a healthcare company worldwide. It operates through two segments, Pharmaceutical and Animal Health. The Pharmaceutical segment offers human health pharmaceutical ...